Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 16, 2020
Daily News
January 16, 2020
- Impact of Oligonucleotides - 1: Onpattro a Major Advance in FAP Treatment, but Challenges Remain
January 16, 2020
- Takeda’s RCC Drug Cabometyx in MHLW Panel’s Review Roster for January 29; Alecensa, Opdivo and More
January 16, 2020
- Asahi Kasei Closes Veloxis Acquisition
January 16, 2020
- JT Grabs Japan Rights to Dermavant’s Psoriasis/Eczema Drug
January 16, 2020
- Japan Forgoes Creation of Medical Fee to Reward Hospital Formularies in 2020 Reform
January 16, 2020
- HIV Meds Dovato, Pifeltro to Join NHI Price List on January 22
January 16, 2020
- Australia to Provide Expedited Reviews for OTC and Quasi-Drugs Approved in Japan
January 16, 2020
- Rotavirus Vaccine to Be Included in Public Vaccination Programs Starting Oct. 1
January 16, 2020
- Orix to Acquire Majority Stake in Generic Drug Maker Kobayashi Kako
January 16, 2020
- ASKA Bags Japan Rights for Cervical Dysplasia Therapy from Kyoto Univ. Spinoff
January 16, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…